Cost-Effectiveness of Recombinant Tissue-Type Plasminogen Activator Within 3 Hours of Acute Ischemic Stroke: Current Evidence [Clinical Sciences]

Conclusions—
Our analysis supports earlier economic evaluations that r-tPA is a cost-effective method to treat stroke. Appropriate use of r-tPA should be prioritized nationally.

Source: Stroke - September 22, 2014 Category: Neurology Authors: Boudreau, D. M., Guzauskas, G. F., Chen, E., Lalla, D., Tayama, D., Fagan, S. C., Veenstra, D. L. Tags: Emergency treatment of Stroke, Thrombolysis Clinical Sciences Source Type: research